2025
Real-Life Performance of Automated Insulin Delivery Systems for High-Carbohydrate Meals: Are All Systems the Same?
Zanfardino A, Ippolito G, Ozen G, Galderisi A, Rollato A, Chianese A, Testa V, del Giudice E, Scaramuzza A, Iafusco D. Real-Life Performance of Automated Insulin Delivery Systems for High-Carbohydrate Meals: Are All Systems the Same? Diabetes Technology & Therapeutics 2025 PMID: 40170658, DOI: 10.1089/dia.2025.0106.Peer-Reviewed Original ResearchHigh-carbohydrate mealInsulin deliveryPostprandial blood glucose levelsType 1 diabetesControl-IQBlood glucose levelsPostprandial glycemic responseNo significant differenceBolus strategyGlycemic controlGlucose levelsAutomated Insulin DeliverySignificant differenceBolusGlycemic responseInsulin bolusMiniMed 780GCorrection bolusesTarget rangeHigh-carbohydratePizza consumptionDelivery systemInsulin delivery systems
2024
Changing patterns of cigarette and ENDS transitions in the USA: a multistate transition analysis of adults in the PATH Study in 2017–2019 vs 2019–2021
Brouwer A, Jeon J, Jimenez-Mendoza E, Land S, Holford T, Friedman A, Tam J, Mistry R, Levy D, Meza R. Changing patterns of cigarette and ENDS transitions in the USA: a multistate transition analysis of adults in the PATH Study in 2017–2019 vs 2019–2021. Tobacco Control 2024, tc-2023-058453. PMID: 39174323, PMCID: PMC12080509, DOI: 10.1136/tc-2023-058453.Peer-Reviewed Original ResearchElectronic nicotine delivery systemsPopulation Assessment of Tobacco and Health StudyLung injury outbreakAge groupsDual usePatterns of cigaretteNicotine delivery systemsENDS initiationAdult age groupsDual usersCigarette initiationPublic health implicationsHealth StudyCigaretteMultistate transition modelDelivery systemAdultsHealth implicationsEndophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab Summary of Cases during Clinical Trial Development
Eichenbaum D, Freeman W, Chang M, Brooks L, Chaudhry N, Dadgostar H, McCannel C, Michels M, Mittra R, Wolfe J, Beindl V, Jaycock P, Bobbala A, Gune S, Spicer G, Callaway N. Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab Summary of Cases during Clinical Trial Development. Ophthalmology Retina 2024, 9: 127-143. PMID: 39154860, DOI: 10.1016/j.oret.2024.08.005.Peer-Reviewed Original ResearchPort Delivery SystemEndophthalmitis casesConjunctival complicationsFollow-upNeovascular age-related macular degenerationBox warningTreated with intravitreal antibioticsAge-related macular degenerationMonthly intravitreal ranibizumabRisk of endophthalmitisPDS implantUS Prescribing InformationImmediate postoperative periodClinical trial developmentETDRS lettersIntravitreal antibioticsIntravitreal ranibizumabDelivery systemSafety populationVisual outcomeMacular degenerationOcular proceduresRetrospective reviewVision lossEndophthalmitisUse of ENDS devices and modifications to vape cannabis among adolescents and young adults who also vape nicotine
Ouellette R, Morean M, Lee J, Kong G. Use of ENDS devices and modifications to vape cannabis among adolescents and young adults who also vape nicotine. Addictive Behaviors 2024, 157: 108099. PMID: 39003977, DOI: 10.1016/j.addbeh.2024.108099.Peer-Reviewed Original ResearchElectronic nicotine delivery systemsVaping cannabisCo-use of cannabisVape pensElectronic nicotine delivery systems useVaping devicesMultivariate logistic regression modelNicotine delivery systemsYoung adultsElectronic nicotine delivery systems devicesCannabis useLogistic regression modelsNicotine liquidVaping nicotineNicotineCannabis concentratesCannabisCo-useAYAE-liquidsVaping productsSocio-economic statusDelivery systemTobacco productsDaysModification of Electronic Nicotine Delivery Systems Among Adolescents and Young Adults.
Kong G, Lee J, Ouellette R, Morean M. Modification of Electronic Nicotine Delivery Systems Among Adolescents and Young Adults. 2024, 154 PMID: 38881359, PMCID: PMC11211691, DOI: 10.1542/peds.2023-063984.Peer-Reviewed Original ResearchElectronic nicotine delivery systemsNicotine e-liquidNicotine delivery systemsDisposable podsPerception of reduced harmE-liquidsDelivery systemYoung adultsNicotine vapingNicotineSocial mediaCannabisLogistic regressionAYAAssess awarenessWeb sitesSource of informationInformation sourcesPrevention effortsDisposable devicesVapingENDS usePotential harmAdolescents326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
TURNER L, SHERR J, ZAHARIEVA D, BARAN J, BODE B, BROWN S, BZDICK S, MEI CHURCH M, HANSEN D, KINGMAN R, LAFFEL L, SHAH V, STONE S, VIENNEAU T, HUYETT L, DUMAIS B, LY T, RIDDELL M, 5 EXERCISE RESEARCH GROUP O. 326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System. Diabetes 2024, 73 DOI: 10.2337/db24-326-or.Peer-Reviewed Original ResearchGeneralized Estimating EquationsInternational Society for Pediatric and Adolescent DiabetesActivity sessionsEstimating EquationsType 1 diabetesExerciseAdolescent DiabetesAF-30Glucose declineDeliveryInsulin deliveryInsuletSessionsDelivery systemInsulin delivery systemsDiabetesAutomated deliveryOmnipodRiskGlucoseT1DPeopleSources of exposure to non-tobacco nicotine electronic nicotine delivery systems and associations with susceptibility to use and use behaviors among young adults in the United States
Li W, Kong G, Davis D, Bold K, Krishnan-Sarin S, Camenga D, Morean M. Sources of exposure to non-tobacco nicotine electronic nicotine delivery systems and associations with susceptibility to use and use behaviors among young adults in the United States. PLOS ONE 2024, 19: e0299533. PMID: 38718067, PMCID: PMC11078344, DOI: 10.1371/journal.pone.0299533.Peer-Reviewed Original ResearchConceptsElectronic nicotine delivery systemsAssociated with greater oddsNicotine delivery systemsGreater oddsYoung adultsTobacco product useTobacco-free nicotineDelivery systemLifetime useENDS usePast-monthExamined associationsNicotineSocial mediaPrevention effortsOddsAdultsSusceptibilityAnalyzed online survey dataStreaming platformsExposureGlycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System
DeSalvo D, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, MacLeish S, Sherr J, Hansen D, Ly T. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics 2024, 26: 383-393. PMID: 38277156, DOI: 10.1089/dia.2023.0506.Peer-Reviewed Original ResearchType 1 diabetesExtension phaseEpisodes of diabetic ketoacidosisEpisodes of severe hypoglycemiaLong-term safetyLong-term useStandard therapyDiabetic ketoacidosisAutomated Insulin DeliverySevere hypoglycemiaYoung childrenConclusion:</i></b>Continuous glucose monitoring metricsExtension studyMethods:</i></b>MonthsGlycemic outcomesTarget rangeTrialsOmnipodHbA1cInsulin deliveryDelivery systemInsulin delivery systemsEpisodesReal-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Forlenza G, DeSalvo D, Aleppo G, Wilmot E, Berget C, Huyett L, Hadjiyianni I, Méndez J, Conroy L, Ly T, Sherr J. Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 514-525. PMID: 38375861, DOI: 10.1089/dia.2023.0578.Peer-Reviewed Original ResearchGlucose targetsType 1 diabetesSubgroup analysisGlycemic outcomesReal-world evidenceMultiple daily injectionsYounger age groupsBaseline characteristicsDaily injectionsRetrospective analysisClinical trialsMedian percentageAge groupsResults:</i></b>OmnipodDelivery systemOutcomesInsulin delivery systemsT1DSubgroupsDiverse sample
2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
Criego A, Carlson A, Brown S, Forlenza G, Bode B, Levy C, Hansen D, Hirsch I, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, MacLeish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T, Group F. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 26: 11-23. PMID: 37850941, PMCID: PMC10794844, DOI: 10.1089/dia.2023.0364.Peer-Reviewed Original ResearchConceptsAdolescents/adultsPivotal trialsInsulin delivery systemsSingle-arm multicenter trialYears of useClinical trial registrationType 1 diabetesLong-term safetyMonths of useLong-term useDiabetic ketoacidosisMulticenter trialSevere hypoglycemiaTRIAL REGISTRATIONGlycemic outcomesType 1Delivery systemExtension phaseMonthsTrialsTarget rangeAdultsHbA1cChildrenEpisodesUse of a polymeric implant system to assess the neurotoxicity of subacute exposure to 2,2′,5,5′-tetrachlorobiphenyl-4-ol, a human metabolite of PCB 52, in male adolescent rats
Wang H, Bullert A, Li X, Stevens H, Klingelhutz A, Ankrum J, Adamcakova-Dodd A, Thorne P, Lehmler H. Use of a polymeric implant system to assess the neurotoxicity of subacute exposure to 2,2′,5,5′-tetrachlorobiphenyl-4-ol, a human metabolite of PCB 52, in male adolescent rats. Toxicology 2023, 500: 153677. PMID: 37995827, PMCID: PMC10757425, DOI: 10.1016/j.tox.2023.153677.Peer-Reviewed Original ResearchConceptsPersistent organic pollutantsPolychlorinated biphenylsPolymeric implantsDrug delivery systemsPCB 52Tandem mass spectrometryOrganic pollutantsMass spectrometryGas chromatographySustained releaseDelivery systemHuman metabolitesHole-board testAdolescent Sprague DawleyMale adolescent ratsAnxiety-like behaviorOpen field testLoading concentrationStraightforward methodHydroxylated metabolitesSubacute neurotoxicitySubacute exposureImmune inhibitionNeurotoxic outcomesSprague-DawleyAdult Electronic Nicotine Delivery System Use in the USA: a Scoping Review Through a Health Equity Lens
Suttiratana S, Kong G, Li W, Ouellette R, Balasuriya L, Funaro M, Arnold C, Krishnan-Sarin S. Adult Electronic Nicotine Delivery System Use in the USA: a Scoping Review Through a Health Equity Lens. Current Addiction Reports 2023, 10: 825-836. PMID: 39372844, PMCID: PMC11452013, DOI: 10.1007/s40429-023-00521-3.Peer-Reviewed Original ResearchElectronic nicotine delivery systemsHealth equity lensElectronic nicotine delivery systems (ENDS) usePopulation health strategiesEquity lensNicotine delivery systemsUS National SurveyCigarette cessationIntervention trialsHealth strategiesENDS useHealth disparitiesReviewThe objectiveHealth equityHealth influencesDemographic characteristicsEthnic differencesLongitudinal studyScoping ReviewNational surveySummaryThe useMost studiesDelivery systemReviewLevel factorsPsychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers
Hood K, Polonsky W, MacLeish S, Levy C, Forlenza G, Criego A, Buckingham B, Bode B, Hansen D, Sherr J, Brown S, DeSalvo D, Mehta S, Laffel L, Bhargava A, Huyett L, Vienneau T, Ly T. Psychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers. Pediatric Diabetes 2023, 2023: 8867625. PMID: 40303234, PMCID: PMC12017088, DOI: 10.1155/2023/8867625.Peer-Reviewed Original ResearchType 1 diabetesGlycemic outcomesInsulin delivery systemsPsychosocial outcomesSleep qualityDiabetes-related distressCaregivers of childrenRegression analysisBaseline characteristicsDelivery systemProspective studyClinical trialsLinear regression analysisPsychosocial measuresParticipant characteristicsDiabetesCaregiversOutcomesOmnipodChildrenAdolescentsTrialsMonthsAdditional benefitSignificant improvementSmall interfering RNA-based nanotherapeutics for treating skin-related diseases
Chang Y, Huang T, Alalaiwe A, Hwang E, Fang J. Small interfering RNA-based nanotherapeutics for treating skin-related diseases. Expert Opinion On Drug Delivery 2023, 20: 757-772. PMID: 37088710, DOI: 10.1080/17425247.2023.2206646.Peer-Reviewed Original ResearchConceptsDifferent nanoparticle typesMechanism of RNAiRNA interferenceSkin delivery systemsLarge-scale productionNanoparticle productsSiRNA deliveryNanoparticle typesSiRNA applicationCutaneous targetingSkin targetingSkin disease managementSkin deliveryPotential applicationsDelivery systemGreat potentialNanocarriersNanotherapeuticsSkin-related diseasesSkin therapySkin penetrationNucleic acidsImproved targetingNanoparticlesTargetingTwo‐Year Outcomes After Pediatric In‐Office Tympanostomy Using Lidocaine/Epinephrine Iontophoresis and an Automated Tube Delivery System
Waldman E, Ingram A, Vidrine D, Gould A, Zeiders J, Ow R, Thompson C, Moss J, Mehta R, McClay J, Brenski A, Gavin J, Ansley J, Yen D, Chadha N, Murray M, Kozak F, York C, Brown D, Grunstein E, Sprecher R, Sherman D, Schoem S, Puchalski R, Hills S, Harfe D, England L, Syms C, Lustig L. Two‐Year Outcomes After Pediatric In‐Office Tympanostomy Using Lidocaine/Epinephrine Iontophoresis and an Automated Tube Delivery System. Otolaryngology 2023, 169: 692-700. PMID: 37003297, DOI: 10.1002/ohn.336.Peer-Reviewed Original ResearchConceptsEpinephrine iontophoresisTube placementTube retentionOperating roomChildren ages 6 monthsCohort of patientsTwo-Year OutcomesAge 6 monthsDelivery systemComplication rateGeneral anesthesiaLocal anesthesiaOtolaryngology practiceTympanostomyPatientsMonthsIontophoresisTympanic membraneAnesthesiaTube displacementAdditional leadsCohortDelivery resultsOutcomesEarNanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment
Chang J, Yu B, Saltzman W, Girardi M. Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment. JID Innovations 2023, 3: 100197. PMID: 37205301, PMCID: PMC10186617, DOI: 10.1016/j.xjidi.2023.100197.Peer-Reviewed Original ResearchProspective predictors of electronic nicotine delivery system initiation in tobacco naive young adults: A machine learning approach
Atuegwu N, Mortensen E, Krishnan-Sarin S, Laubenbacher R, Litt M. Prospective predictors of electronic nicotine delivery system initiation in tobacco naive young adults: A machine learning approach. Preventive Medicine Reports 2023, 32: 102148. PMID: 36865398, PMCID: PMC9971268, DOI: 10.1016/j.pmedr.2023.102148.Peer-Reviewed Original ResearchElectronic nicotine delivery systemsENDS initiationYoung adultsPrevention programsProtective factorsLongitudinal cohort surveyProspective predictorsNicotine delivery systemsWave 4Cohort surveyPhysical exerciseTobacco productsWave 4 dataAdultsPredictorsMarijuana useFurther investigationRiskInitiationRepresentative dataDelivery systemPopulation AssessmentSusceptibilityCigarettesStudyDiabetes Technology Meeting 2022
Huang J, Yeung A, DuBord A, Wolpert H, Jacobs P, Lee W, Drincic A, Spanakis E, Sherr J, Prahalad P, Fleming A, Hsiao V, Kompala T, Lal R, Fayfman M, Ginsberg B, Galindo R, Stuhr A, Chase J, Najafi B, Masharani U, Seley J, Klonoff D. Diabetes Technology Meeting 2022. Journal Of Diabetes Science And Technology 2023, 17: 1085-1120. PMID: 36704821, PMCID: PMC10347991, DOI: 10.1177/19322968221148743.Peer-Reviewed Case Reports and Technical NotesConceptsDiabetes technologyPainful diabetic neuropathyDiabetic foot ulcersSpinal cord stimulationContinuous glucose monitoringElectronic health recordsDiabetic neuropathyFoot ulcersCord stimulationDiabetes careInsulin delivery systemsInsulin pensMeasurement of glucoseGlucose monitor dataGlucose monitoringInsulin deliveryHealth recordsContinuous glucose monitor dataNovel insulinInsulinDelivery systemDigital healthNeuropathyHypoglycemiaUlcersGene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors
Ovsepian S, Waxman S. Gene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors. Nature Reviews Neuroscience 2023, 24: 252-265. PMID: 36658346, DOI: 10.1038/s41583-022-00673-7.Peer-Reviewed Original ResearchIntradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy
You Y, Tian Y, Yang Z, Shi J, Kwak K, Tong Y, Estania A, Cao J, Hsu W, Liu Y, Chiang C, Schrank B, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Li X, Wang Y, Lu W, Bahrani E, Lee L, Teng L, Jiang W, Lan F, Kim B, Lee A. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023, 7: 887-900. PMID: 36635419, DOI: 10.1038/s41551-022-00989-w.Peer-Reviewed Original ResearchConceptsExtracellular vesiclesTranslation of genetic materialFunctional proteinsGenetic materialIntradermal deliveryRNA therapeuticsPhotoaged skinHuman dermal fibroblastsType I collagenMessenger RNA therapeuticsProtein replacement therapyTreatment of photoaged skinCOL1A1 mRNAVesiclesMRNADermal fibroblastsTissues of miceEncapsulated mRNAReduced wrinkle formationProteinTherapyDelivery systemReplacement of collagenMicroneedle arraysCollagen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply